AP-SA02

Armata Pharmaceuticals, Inc. · Phase 1 active Biologic

At a glance

Generic name	AP-SA02
Sponsor	Armata Pharmaceuticals, Inc.
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

AP-SA02 CI brief — competitive landscape report
AP-SA02 updates RSS · CI watch RSS
Armata Pharmaceuticals, Inc. portfolio CI